SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer

Patients with polycystic kidney disease (PKD) encounter a high risk of clear cell renal cell carcinoma (ccRCC), a malignant tumor with dysregulated lipid metabolism. SET domain–containing 2 (SETD2) has been identified as an important tumor suppressor and an immunosuppressor in ccRCC. However, the ro...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Hanyu, Liu, Changwei, Wang, Aiting, Ma, Chunxiao, Xu, Yue, Ye, Tianbao, Su, Wenqiong, Zhou, Peijun, Gao, Wei-Qiang, Li, Li, Ding, Xianting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663509/
https://www.ncbi.nlm.nih.gov/pubmed/37989747
http://dx.doi.org/10.1038/s41467-023-43378-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10663509/
https://www.ncbi.nlm.nih.gov/pubmed/37989747
http://dx.doi.org/10.1038/s41467-023-43378-w

Ejemplares similares